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Circulating endothelial cell-derived 
extracellular vesicles mediate the 
acute phase response and sickness 
behaviour associated with CNS 
inflammation
Yvonne Couch  1, Naveed Akbar2, Jay Roodselaar  3, Matthew C. Evans3, Chris Gardiner  4, 
Ian Sargent5, Ignacio A. Romero6, Adrian Bristow7, Alastair M. Buchan1, Norman Haughey8 & 
Daniel C. Anthony  3
Brain injury elicits a systemic acute-phase response (APR), which is responsible for co-ordinating the 
peripheral immunological response to injury. To date, the mechanisms responsible for signalling the 
presence of injury or disease to selectively activate responses in distant organs were unclear. Circulating 
endogenous extracellular vesicles (EVs) are increased after brain injury and have the potential to carry 
targeted injury signals around the body. Here, we examined the potential of EVs, isolated from rats 
after focal inflammatory brain lesions using IL-1β, to activate a systemic APR in recipient naïve rats, 
as well as the behavioural consequences of EV transfer. Focal brain lesions increased EV release, and, 
following isolation and transfer, the EVs were sequestered by the liver where they initiated an APR. 
Transfer of blood-borne EVs from brain-injured animals was also enough to suppress exploratory 
behaviours in recipient naïve animals. EVs derived from brain endothelial cell cultures treated with 
IL-1β also activated an APR and altered behaviour in recipient animals. These experiments reveal that 
inflammation-induced circulating EVs derived from endothelial cells are able to initiate the APR to brain 
injury and are sufficient to generate the associated sickness behaviours, and are the first demonstration 
that EVs are capable of modifying behavioural responses.
Any local damage to an organ, including the central nervous system (CNS), produces some degree of systemic 
inflammation by activating the acute-phase response (APR). Inter-organ communication by humoral factors 
such as cytokines is often suggested as a mechanism for the induction of the APR, and release of acute-phase pro-
teins (APPs) into the circulation1. Following injury to the brain, the hepatic release of APPs occurs before there 
is significant evidence of an inflammatory response in the brain2, 3. TNF4, 5 and CXCL12, 6 both fall into the APP 
category, and are rapidly synthesised by the liver as part of the APR in response to CNS injury.
The purpose of the APR is to promote the neutralization of pathogens by mobilizing the appropriate leukocyte 
populations, whilst simultaneously initiating repair processes. However, it is clear that over-activation of an APR 
can be detrimental7. The argument for humoral communication from the CNS to activate the APR post-injury 
is complicated by the lack of export sequences on cytokines produced in the CNS8. Indeed, experiments with 
recombinant cytokines, injected directly into the brain parenchyma or into the blood, suggest that the local 
release of free cytokine from the CNS into the circulation to target peripheral organs is not a major pathway2, 9, 10. 
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Therefore, whilst the brain can mount a significant local inflammatory response to injury, the mechanisms by 
which this is communicated to the periphery remain unclear.
Extracellular vesicles (EVs) are membrane-enclosed vesicles comprising larger (100nm-1µm) microvesicles 
(MV), formed by the outward budding and fission of the plasma membrane, and exosomes, which are smaller 
(<200 nm) and formed by the endocytic invagination of endosomal membranes and stored in multivesicular 
bodies (MVB)11. Platelet-derived EVs are produced in large numbers, but EVs have also been shown to be pro-
duced by leukocytes12, endothelial cells13, neutrophils14 and macrophages15.
Whilst the presence of EVs in the blood is a normal physiological phenomenon, many pathologies have been 
found to be associated with considerable increases in circulating EVs, including inflammatory and autoimmune 
diseases, atherosclerosis, and malignancies16, 17. Brain injury and disease is no exception, however the role of 
circulating EVs in CNS pathology has remained unclear18. Endothelial cells are placed conveniently at the junc-
tion between the CNS and the circulation and - playing a key role in barrier function - seem an ideal candidate 
for EV-mediated communication of CNS injury19. For example, in acute ischemic stroke, endothelial EVs have 
been shown to be positively correlated with lesion volume and stroke outcome20, but, once again, it is not clear 
whether they contribute to the pathogenesis of stroke, or whether they are simply produced as a consequence of 
it. Ischaemic stroke is known to generate a significant systemic APR21, and as such endothelial EVs may have a 
role in co-ordinating the inter-organ inflammatory signalling pathways responsible for this, and thus provide a 
particularly compelling route for CNS-liver communication. Indeed, recent studies have shown that endothelial 
EVs are capable of transferring molecules to leukocytes during CNS inflammation22, however, as so little is cur-
rently known about the role of CNS EVs per se, studies in a basic model of CNS inflammation are key to future 
understanding of their role in disease.
Against this background, we sought to study the function of circulating EVs following the induction of a focal 
interleukin-1β (IL-1β)-induced inflammatory lesion within the brain parenchyma, followed by blood fraction-
ation to transfer EVs between animals to test the hypothesis that EVs elicited after injury are a key mediator of 
CNS-liver communication. Compared to other acute brain injury models, the IL-1β challenge generates a focal 
inflammatory response with stereotypical sickness behaviours5 in the absence of blood-brain barrier breakdown 
or acute cell death in adult animals23. The single-bolus injection of IL-1β employed here induces de novo synthesis 
of endogenous IL-1β24 by microglia and endothelial cell activation25, 26, as well as continued leukocyte recruitment 
for up to seven days24. We used this approach to investigate whether the transfer of the EV fraction alone, from 
the blood of an IL-1β-challenged animal to a naïve animal, would result in an increase in hepatic APPs and the 
subsequent associated sickness behaviours5, 10, 27. Confirmation that EVs from brain endothelial cells alone could 
account for the molecular and behavioural changes observed was obtained from cultured brain vascular endothe-
lial cells exposed to an IL-1β challenge. The results described here show that not only are EVs able to initiate an 
APR, but they are also able to activate the sickness behaviours associated with injury or infection, thus showing 
that more complex behavioural phenotypes can be transferred simply by transferring only the EV fraction of the 
blood. The recognition that EVs are not simply passive biomarkers of disease, but a targeted inter-organ com-
munication system provides a whole new avenue for the development of future therapies treating inflammatory 
disease in the brain and, most likely, peripheral inflammatory pathologies.
Results
Number of circulating EVs increases in animals after central IL-1β injection. EV release occurs 
under normal physiological conditions, and has been shown to increase in inflammatory pathologies28. To deter-
mine whether CNS inflammation elicited an increase in EVs, we employed a generic model of CNS inflamma-
tion2, 24, 29, 30. Animals were allowed to survive for 2 hours after the stereotactic microinjection of IL-1β (10ng) into 
the brain (striatum), which has been previously shown to generate a significant NFkB-dependent acute phase 
response in the liver2, 31 in the absence of any increase in IL-1β in the plasma (supplementary Fig. S1) We used 
nanoparticle tracking analysis (NTA) to determine the size and number of EVs in the blood after the injec-
tion. Compared to vehicle, IL-1β increased the number of circulating EVs (Fig. 1a,b,c). In particular, there was 
a peak in particles of approximately 200 nm (Fig. 1a), with a significant treatment:size interaction (F50,510 = 9.79, 
p < 0.0001; Fig. 1a). Despite this interaction, there was no difference in size of EVs overall (Fig. 1d), and the 
increase in EV number was seen for both small (<200 nm; Fig. 1b) and total EV populations (Fig. 1c), suggest-
ing that size distribution was largely unaltered by IL-1β treatment (Student’s t-test p < 0.0001 and p < 0.001, 
respectively).
We next sought a candidate cell type that could be responsible for the increased production of EVs, and for this 
we used a rat endothelial cell culture model, because of the position of the endothelial cells, poised as they are at 
the junction of the CNS and periphery, and their known response to pro-inflammatory signals24, 32, 33. Our EV pop-
ulation from our IL-1β injected animals was shown to be enriched for CD31 out of proportion to CD41 expres-
sion (supplementary Fig. S2), supporting an endothelial cell origin. We therefore challenged rat brain vascular 
endothelial cells (GP-8 rat brain-derived) with IL-1β (1ng/ml) for 2 hours, so that the time frame was comparable 
to the in vivo experiments. IL-1β significantly increased EV shedding compared to controls (Fig. 1e, f, g), with a 
peak in particles of 200 nm and a significant interaction between treatment and size (F50,204 = 4.16, p < 0.0001). In 
a similar manner to the in vivo model, we detected no overall change in size of the EVs (Fig. 1h), but an increase 
in smaller EVs (<200 nm; Student’s t-test p < 0.05; Fig. 1f). Thus brain endothelial cells are clearly capable of 
shedding EVs in response to the presence of IL-1β. It should be noted that no IL-1β could be detected in the EV 
fraction or in the ultracentrifuged, pooled EV-free fraction (supplementary Fig. S1).
Transfer of EV fraction after inflammatory challenge results in a hepatic inflammatory 
response. Previous work from our group has shown that a pro-inflammatory insult to the CNS causes an 
early hepatic response, with induction of NFκB-regulated genes, including pro-inflammatory cytokines and 
www.nature.com/scientificreports/
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Figure 1. Extracellular vesicle (EV) release in vivo and in vitro after an IL-1β challenge. Animals received a 
single injection of IL-1β (10ng in 1 µl into CNS parenchyma within the striatum) or vehicle (saline) and blood 
was taken at 2 hours and analysed for EV number and size using Nanosight Tracking Analysis. Distribution 
in vehicle and IL-1β treated animals demonstrated a mixed population of vesicles (a - graph; EM inset). This 
was quantified as EVs × 1010/ml by NTA for vesicles <200 nm (b) as well as for total vesicles (c). Average size 
of the EV population in nm was also determined (d). Brain vascular endothelial cells (GP-8) were treated 
with IL-1β (10ng/ml) for 2 hours and supernatant was harvested and analysed for EV size and number using 
NTA. Distribution in vehicle and IL-1β treated cells demonstrated a mixed population of vesicles (e - graph; 
EM inset). This was quantified as EVs × 106/ml by NTA for vesicles <200 nm (f), as well as for total vesicles 
(g). Average size of the EV population in nm was also determined (h). Data are mean ± SEM, n = 6, *p < 0.05; 
**p < 0.01 and ***p < 0.001. Scale bars on micrographs show 0.2 µm and 50 nm (inset).
www.nature.com/scientificreports/
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chemokines9, 34, leading to neutrophil recruitment. In order to find out whether the circulating EVs released from 
the CNS after an IL-1β challenge were capable of inducing a hepatic inflammatory response, EV-free plasma 
supernatant and EV fractions were pooled and transferred from donor animals, injected with either IL-1β or 
saline, into naïve recipient animals (Fig. 2a).
Using quantitative PCR we showed that EV-free supernatant from the plasma of IL-1β treated animals does 
not induce TNF mRNA expression in the liver (Fig. 2b) but the EV fraction, isolated from EV-free supernatant 
and introduced into naïve animals, induced a 5-fold increase in TNF mRNA expression compared to vehicle 
controls (Student’s t-test; p < 0.05; Fig. 2c). Plasma-derived EV-free supernatant transfer induced a small increase 
in CXCL-1 mRNA in IL-1β injected animals compared with EV-free supernatant from vehicle treated animals 
(Student’s t-test p < 0.05; Fig. 2e). The transfer of the EV fraction from IL-1β challenged animals to naïve animals 
resulted in a large increase in CXCL-1 expression (p < 0.05; Fig. 2f). As was the case for the in vivo transfer, EVs 
derived from IL-1β treated cells significantly increased production of TNF (Student’s t-test p < 0.05; Fig. 2d) and 
CXCL-1 (p < 0.001; Fig. 2g) compared with injection of EVs from saline treated cells. Thus, not only is the EV 
fraction sufficient for transfer of a pro-inflammatory state in the liver, but EVs isolated specifically from rat brain 
vascular endothelial cells are sufficient for this purpose.
Finally, given that one of the consequences of increased hepatic chemokine expression is neutrophil 
chemotaxis, we examined the livers of the recipient rats using light microscopy using an in-house generated 
anti-neutrophil antibody. For in vivo-derived EVs transferred to recipient rats, there were significantly more neu-
trophils in rats given EVs compared with vehicle (p < 0.0001; Fig. 3b), a pattern that was recapitulated with rats 
given in vitro-generated EVs treated with IL-1β compared with vehicle (p < 0.0001; Fig. 3c). However, in addition 
to this, there were also increased numbers of neutrophils in the livers of rats given EV-free plasma compared with 
saline (p < 0.0001; Fig. 3a), suggesting that both the EVs, and some humoral substance, are capable of causing 
hepatic neutrophil chemotaxis.
EVs generated from IL-1β-treated rats track to hepatic Kupffer cells. We next wished to examine 
whether EVs injected systemically in recipient rats localized to the liver. To achieve this we fluorescently labelled 
extracted EVs with the membrane dye PKH-67, before injecting them into a cohort of recipient rats, and then 
analysed specific organs using fluorescent microscopy. Whilst fluorescence was largely absent from other organs 
such as the spleen, lung and heart (supplementary Fig. S4), it was detectable in the liver (Fig. 3d). We suspected 
that the Kupffer cell population would be responsible for this uptake through phagocytosis, and co-labelling 
with the macrophage marker CD11b showed good co-localization of fluorescence signal (Fig. 3d), in support of 
this hypothesis. Here, it should be noted that free dye injected into animals does not result in labelling (Fig. 3e). 
Further evidence in support of this hypothesis was found in animals pre-treated with clodronate liposomes. These 
deplete peripheral macrophage populations, including liver Kupffer cells. In animals treated with clodronate, an 
i.v. injection of IL-1β EVs generated from GP-8 cells failed to elicit an inflammatory response to the same degree 
as IL-1β EVs and empty liposomes (Fig. 4). Indeed, TNF expression was significantly increased after animals 
received EVs from IL-1β treated endothelial cells when compared to saline/clodronate treated animals (Student’s 
t-test p < 0.01; Fig. 4a), and this increase was reduced in animals receiving EVs/clodronate (p < 0.05; Fig. 4a). 
CXCL-1 expression showed a similar pattern, with a significant increase in EV treated animals when compared to 
saline/clodronate animals (p < 0.05; Fig. 4b) which was slightly decreased in animals receiving clodronate prior 
to EVs.
Extracellular vesicles are capable of inducing sickness-behaviour in recipient animals. Previous 
studies from our group have shown that inflammatory insults to the brain result in “depression-like” sickness 
behaviours, that are at least partly dependent on cytokine and chemokine expression in the liver5, 10, 35. Thus, given 
that we have shown that transfer of EVs from IL-1β-treated rats and rat-derived endothelial cells migrate to the 
liver, thereby inducing a hepatic acute phase response, it seemed intuitive that this might also result in the transfer 
of sickness behaviours to recipient rats.
We used the open field paradigm to measure the number of rears performed by each animal and the number 
of squares crossed, a well-validated measure of exploratory behaviour that shows significant changes in models 
of sickness behaviour27, 35, 36. For the in vivo transfer of EVs, recipient rats showed significantly fewer rears on 
the open field (Student’s t-test; p < 0.05; Fig. 5a,b), and a trend to fewer number of squares crossed (Fig. 5c,d). 
We found a similar result for recipient rats injected with in vitro-generated EVs, with significantly fewer rears 
(Student’s t-test; p < 0.05; Fig. 5e) and squares crossed on the open field (p < 0.05; Fig. 5f). Taken together this is 
the first published report of a behavioural phenotype resulting from the transfer of EVs from “sick” animals/cells 
to healthy recipients, and highlights how systemic and wide-ranging the role is of EVs.
Discussion
Injury to the CNS normally results in the induction of a systemic acute phase response (APR), which is capable 
of exacerbating the central injury. Abrogation of this response could prove useful in acute injuries, such as trau-
matic brain injury or stroke. Until now the signals responsible for the activation of the APR after brain injury 
were not known, but speculated to be humoral or neural. Our study shows that brain endothelial cell-derived 
extracellular vesicles (EVs) are sufficient to mediate not only brain-liver communication after injury, but also 
inflammation-induced sickness behaviour. The striking observation that the circulating EV fraction is sufficient 
to elicit an APR when they are transferred from a brain-injured animal to a naïve animal, reveals that non-neural, 
non-humoral communication provides an explanation for the selective activation of the peripheral APR, and pro-
vides a new target for therapeutic intervention in acute brain injury. In addition, discovery that the EV fraction 
from an injured animal is sufficient to elicit sickness behaviours in the recipient was wholly unexpected and as 
such introduces an entirely new concept of EV mediated behaviour to the psychoneuroimmunology field.
www.nature.com/scientificreports/
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Figure 2. Schematic overview of in vivo experiments (a). Animals received a single intracranial injection 
of IL-1β or vehicle (saline) and blood was collected and processed for EV isloation. Platelet free plasma was 
separated using centrifugation and EVs further separated by ultracentrifugation. Samples from 3 ‘donor’ 
animals were pooled and administered to each ‘recipient’ animal. The hepatic response to EV transfer of in vivo 
and in vitro-derived EVs (b–e): EVs or EV-free supernatant were transferred from donor animals challenged 
with IL-1β or saline into naive recipient animals and the hepatic response was studied after 4 hours. Specifically, 
expression of TNF mRNA in naïve animals receiving EV-free supernatant (b); EVs isolated from whole blood 
(c) or EVs from GP-8 cell supernatant (d). CXCL-1 mRNA in animals receiving EV-free supernatant (e); 
EVs isolated from whole blood (f) or EVs from GP-8 cell supernatant (g). All qPCR data are normalized to 
the expression of the housekeeping gene GAPDH and then further normalized to control animals. Data are 
mean ± SEM, n = 6, *p < 0.05 and ***p < 0.001.
www.nature.com/scientificreports/
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In this study, we employed a well-characterised model of CNS inflammation to explore brain-liver commu-
nication37, and more specifically the role of endothelial cell-derived EVs in this pathway. The microinjection of 
IL-1β into the brain parenchyma generates a focal inflammatory lesion, and there is known to be no sensible 
leakage of cytokine into the circulation from the brain2, 9. As such, this minimally invasive model lends itself to the 
study of brain-to-peripheral immune system responses. The concentration of IL-1 in the present study is equiva-
lent to that generated after a haemorrhagic stroke38. However, we have previously shown that these IL-1β-induced 
focal brain inflammatory lesions rapidly induce hepatic NFkB-dependent cytokine and chemokine expression31, 
causing mobilisation of leukocytes from the marrow to the blood and then into the injured brain34, as well as 
chemotaxis to the liver2. This pathway has been shown to be reliant on hepatic chemokine production, which is 
also a feature of chronic immune-mediated CNS disease where EVs have been shown to be elevated10.
Broadly, inflammation is known to cause an increase in EV production from a number of cell types. The 
majority of studies focus on platelet-derived EVs but they have also been shown to be produced by leukocytes39, 
endothelial cells13, astrocytes40,  neutrophils14 and macrophages15. Here, we have demonstrated that there is an 
increase in EV release from both the injured CNS, and from brain endothelial cells in culture after IL-1β stim-
ulation. Endothelial cells are likely to be an important mediator of inter-organ signalling in vivo, owing to their 
unique position at the interface of CNS and the blood. Vascular endothelial cells are known to express receptors 
for IL-1β and upregulate markers of inflammation in response to an IL-1β challenge24, 32, 33, as well as to shed 
EVs under pathological conditions19. Vascular cells are exclusively placed at the CNS-immune junction. Given 
Figure 3. Hepatic neutrophil numbers were counted in animals receiving EV-free supernatant (a); EVs isolated 
from whole blood (b) or EVs from GP-8 cell supernatant (c). Representative microscopy of PKH-67-labelled 
EVs (green) introduced into naïve animals tracked to the liver (d) where they were found largely in CD11b-
positive (red) Kupffer cell populations. An administration of PKH-67 intravenously does not result in any 
staining (e). Scale bars on micrographs represent 40 µm.
www.nature.com/scientificreports/
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the findings in this study of elevated TNF and CXCL-1 production after administration of EV-fraction from 
inflammatory challenged animals or cells, it seems that at least one major mechanism underlying this CNS-liver 
inflammatory signalling is the production of vascular endothelial EVs. This theory is supported by the recent 
work of Paul and colleagues, who have demonstrated that endothelial EVs transfer claudin-5 to leukocytes dur-
ing episodes of CNS inflammation22. Whilst our data demonstrate that EVs are shed from endothelial cells in 
response to an IL-1β challenge, it is probable that other cell populations within the CNS may also release EVs that 
contribute to the cross-talk between the injured brain and the peripheral immune system. For example, astrocytes 
generate large membrane-enclosed vesicles that are able to cross membranes40, 41, and it is likely these cells may act 
in concert to co-ordinate the response to injury.
Our data also demonstrate that isolated EV fractions from both IL-1β treated animals, and from IL-1β chal-
lenged cells, are capable of inducing neutrophil recruitment, an effect that was also found for EV-free plasma 
which, taken together, suggests that whilst there is also some humoral molecule capable of signalling hepatic neu-
trophil recruitment, the EVs themselves are sufficient for this process. This finding is consistent with the cytokine 
and chemokine expression, in that CXCL-1 is produced at an elevated level after administration of both EV-free 
plasma and the EV fraction from rats/cells treated with IL-1β, with the latter having an even higher expression. 
CXCL-1 is an important chemokine involved in neutrophil transport42, so we would predict that CXCL-1 expres-
sion and neutrophil recruitment go together, as, indeed, they do here. Interestingly, a recent study by Dickens 
et al.40, has demonstrated that EVs derived from stimulated astrocytes do not produce significant hepatic expres-
sion of CXCL-1 when they are injected into naïve recipients, but they do induce hepatic TNF. This data suggests 
that EVs from distinct cell populations may carry their own unique injury signals to the periphery, and that the 
resultant characteristics of the peripheral immune response is dependent upon the combined effects of the total 
EV population. This phenomenon may enable fine tuning of the peripheral inflammatory response to CNS injury 
to ensure that the most appropriate leukocyte populations are mobilized.
Irrespective of cell of origin, after biogenesis in the CNS, blood-born EVs can be captured by any number of 
inflammatory cells throughout the body. However, our previous data has demonstrated that there is a significant 
hepatic response to CNS injury2. When we administered fluorescent EVs intravenously we found them mainly 
in the liver. We suspected that the EVs were being removed by hepatic Kupffer cells, and our immunofluores-
cent imaging of CD11b + macrophages and labelled EVs, show overlap of fluorescent signal, indicating that the 
sequestration was, predominantly, if not completely, by Kupffer cells. We have shown that Kupffer cells engage in 
hepatic chemokine expression in response to brain injury9. Indeed, the selective depletion of these cells results in 
inhibition of leukocyte recruitment to the injured brain34, suggesting the EV signal from the brain is transduced 
by Kupffer cells into the traditional APR and resultant behaviour known to be associated with CNS injury.
The results described here (both in vitro-derived and in vivo-derived EVs) show that, not only are EVs able 
to initiate an APR, but they are also able to activate the sickness behaviours associated with injury or infection. 
We have previously shown that the circulating and hepatic expression of TNF-α is central to the sickness behav-
iours induced by the inflammatory lesions in the brain5. Etanercept, which is unable to cross the intact BBB, is 
able to block the sickness behaviours induced by the central injection of IL-1β. Therefore, it seems likely that the 
Figure 4. The hepatic response to EV transfer of in vitro-derived EVs in clodronate-treated animals. (a) TNF 
mRNA expression in the liver of animals receiving EVs isolated from IL-1β treated GP-8 cell supernatant 
in the presence or absence of clodronate-filled liposomes (lipo) or denatured EVs (EV den). (b) CXCL-1 
mRNA expression in the liver of animals receiving EVs isolated from IL-1β treated GP-8 cell supernatant in 
the presence or absence of clodronate-filled liposomes. All qPCR data are normalized to the expression of the 
housekeeping gene GAPDH and then further normalized to control animals. Data are mean ± SEM, n = 4; 
‡compared to saline/liposome treated animals; *compared to IL-1β treated animals.
www.nature.com/scientificreports/
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EV-induced hepatic TNF expression has the potential to induce the sickness behaviours observed in the present 
study.
Conclusion
This study clearly highlights the capacity of EVs to alter cellular functions in distant organs. Overall, these data 
demonstrate an important novel mechanism of communication between the CNS and the liver, and provides a 
potential tool for future intervention. Target discovery, both on the surface and within EVs, is likely to provide 
essential evidence for the manipulation of the APR to CNS injury. By being able to intervene rapidly after a stroke 
or a traumatic brain injury, for example, and reduce the subsequent inflammation, we may significantly improve 
clinical outcomes and provide crucial extra time for neurological recovery.
Materials and Methods
Animals. Adult male Wistar rats were obtained from Harlan and housed under a standard 12-hour light/dark 
cycle. Animals were provided with food and water ad libitum. All procedures were carried out in accordance with 
Figure 5. The behavioural response to IL-1β-stimulated, in vivo-derived circulating EVs and in vitro-derived 
brain endothelial EVs. Number of rears and number of squares crossed in the open field are shown for rats given 
in vivo-derived EVs or EV-free plamsa (a–d), and also for EVs from IL-1β and saline-treated endothelial cells 
(e,f). Data are mean ± SEM, n = 6, *p < 0.05 and **p < 0.01.
www.nature.com/scientificreports/
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the UK Animals (Scientific Procedures) Act, 1986 and licenced protocols were approved by local committees 
(LERP and ACER, University of Oxford). Animals were anaesthetized in a 2% isoflurane/oxygen mix (2 L/min) 
and placed in a stereotactic frame (Stoetling Co., USA) under maintenance anaesthesia (1.5%).
Stereotaxic Surgery. All surgical procedures were performed under an operating microscope (Wild M650, 
Leica, Milton Keynes, UK). Recombinant rat interleukin-1β (rrIL-1β; 10ng/µl) (NIBSC, UK) was synthesized and 
stored in PBS until use43. Stereotaxic surgery was performed as described previously44. Briefly, anaesthetised rats 
were held in a stereotaxic frame, a burr hole was drilled in the skull and 1 µl of rrIL-1β was unilaterally micro-
injected into the left striatum through a finely-drawn glass microcapillary needle (tip < 50 µm) over a period of 
5 minutes. The stereotaxic co-ordinates were -1.0 mm A/P, -3.0 mm M/L, and -4.0 mm D/V relative to Bregma. 
The dose of IL-1β in this study was chosen on the basis of our previous experiments and from those of others 
that have provoked a febrile response and behavioural depression36. IL-1β was dissolved in endotoxin-free saline 
(vehicle) and we have shown that the injected IL-1β does not make its way into the circulation45. During the sur-
gical procedures, body temperature was maintained on a heated blanket throughout the period of anaesthesia, 
and the animals were allowed to recover in a heated chamber.
Clodronate Treatment. Animals received either clodronate-filled liposomes or empty liposomes as an i.v. 
injection 24 hours prior to receiving either EVs from IL-1β-stimulated GP-8 cells or denatured EVs. EVs were 
denatured by boiling at 95 °C for 10 minutes.
Nanoparticle Tracking Analysis (NTA). All analyses were performed on a Nanosight NS500 NTA instru-
ment (Malvern Instruments, Amesbury, UK) equipped with a 405 nm violet laser and a CMOS camera 
(Hamamatsu Photonics, Japan) as previously described46. The system uses a finely focused laser beam that is 
introduced to the sample through a glass prism. The beam refracts at a low angle as it enters the sample, resulting 
in a thin beam of laser light that illuminates particles through the sample. Particles resident within the beam are 
visualized using a conventional optical microscope, fitted with a video camera, aligned normally to the beam axis, 
which collects light scattered from all particles in the field of view. The sample chamber is 500 µm deep, but the 
beam depth is around 20 µm at the point of analysis, matching with the depth of focus of the imaging optics. A 
video of typically 60 seconds duration is taken, with a frame rate of 30 frames per second, and particle movement 
is analyzed by NTA software (NanoSight Ltd.). The operator was blinded to the identity of the samples. The sam-
ples were diluted to give a concentration of between 2 × 108 and 10 × 108. All samples were analysed using camera 
level 12. All videos were processed using NTA 2.3 build 17 software with threshold, minimum particle size and 
blur set to automatic. Five videos of 30 seconds were analysed using the following script: PUMPLOAD, 
REPEATSTART, DELAY 5, CAPTURE 30, PRIME, REPEAT 5. A suspension containing a known concentration 
of 100 nm diameter silica beads was analysed at the start and finish of each working day to ensure reproducibility 
of results. The NTA software is optimized to first identify and then track each particle on a frame-by-frame basis, 
and its Brownian movement tracked and measured frame to frame. The velocity of particle movement is used to 
calculate particle size by applying the two-dimensional Stokes-Einstein equation: < > =
piη
x y, K T
d
2
3
B t s
h
( ) where < >x y, 2 
is the mean squared displacement, KB is Boltzmann’s constant, T is the temperature of the solvent in Kelvin, t(s) is 
the sampling time (i.e., 1/30 fpsec = 33 msec), η is the viscosity, and dh is the hydrodynamic diameter.
EV fractions were isolated from either platelet-free plasma or from cell culture supernatant centrifuged at 
10,000 G for 30 minutes to separate out cellular debris. Extracellular vesicle fractions, where appropriate, were 
isolated from the supernatant of this spin using an ultracentrifuge at 120,000 G for 2 hours. Controls for each 
experiment were the supernatant fraction from this spin, derived from either platelet-free plasma or cell cul-
ture supernatant and described henceforth as EV-free supernatant.
Extracellular Vesicle Transfer. EVs were isolated and measured in plasma from whole blood using NTA. For 
transfer experiments EVs were isolated and pooled from three donor animals and injected into one recipient ani-
mal (Fig. 2a). The pooled samples were quantified and each animal received 5 × 109 particles in 0.5 ml of saline i.v.
Cell Culture. Brain vascular endothelial cells (GP-8; ATCC) were cultured under standard conditions (95% 
air, 5% CO2, 37 °C) using DMEM (High Glucose – 4.5 g/L; Life Sciences) and 10% foetal calf serum with antibiotic 
and antimycotic. Cells were passaged using trypsin at 80–90% confluence and treated when confluent. IL-1β was 
used at a concentration of 10ng/ml in DMEM and cells were treated for 2–6 hours. In order to minimize ‘back-
ground’ EVs in serum and medium, both were filtered at 0.22 µm and ultracentrifuged for 18 hours at 120,000 G. 
Medium treated in this way did not affect the growth of the cells. For transfer of vesicles from in vitro cultures to a 
rat, a monolayer of a single T75 flask was used per animal yielding on average 1 × 1010 EVs per ml.
Vesicle Labelling. EV fractions from cell culture experiments were used for in vivo tracking. EVs were iso-
lated by ultracentrifugation as above. The final pellet was resuspended in EV-free PBS and combined 1:1 with 
PKH-67 (Sigma-Aldrich, UK) for 5 minutes in the dark to label the membrane of the EVs. The reaction was 
terminated using EV-free FCS and the labelled EVs were ultracentrifuged at 120,000 g for 2 hours before resus-
pension in EV-free 0.9% saline. For unlabelled, stimulation experiments the resuspended pellet was stored at 4 °C 
in PBS prior to use.
Open Field Testing. Open field testing was carried out as described previously5, 47. The open field consisted 
of a rectangular wooden box 50 cm × 70 cm with 40 cm high walls, the rats were placed into a corner and allowed 
to explore for 3 minutes. Light levels were 350–400 Lux as used in previous experiments48. The movement of the 
animals was recorded on video and exploratory behaviour and rearing behaviour was analysed blind post-hoc. 
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Rearing is considered to be an exploratory behaviour that is motivated by interest rather than a survival instinct 
to explore a novel environment. Distance travelled in an open field reflects the need to survey a new environment 
and will be reduced after the loss of rearing behaviour.
Immunohistochemistry. Animals received an overdose of pentobarbital (i.p.) and were perfused with 0.9% 
saline until the liver was cleared of blood. Fresh liver was snap frozen using an isopentane bath on dry ice. 10 µm 
sections were cut on a cryostat (Leica CM1850) and post-fixed in formalin for 20 minutes before staining with 
CD11b (1:250, Abcam, Cambridge UK), and visualized using a biotinylated secondary antibody (Vectorlabs, UK) 
and streptavidin-linked Texas red (Vectorlabs) for fluorescent labelling. Slides were coverslipped using aque-
ous mounting medium containing DAPI (Vectorlabs). For neutrophil counting experiments, neutrophils were 
labelled with an in-house anti-neutrophil antibody (MBS-1) followed by a biotinylated secondary, developed 
using 3’3-diaminobenzidine and counterstained with haematoxylin. Counts were made using a 1 mm2 graticule 
in three areas on three separate sections and calculated as cells per mm2.
Electron Microscopy. 50 µl of purified EVs in 2% paraformaldehyde was applied to freshly glow-discharged 
carbon 300 mesh copper grids for 5 minutes. Samples were blotted with filter paper, passed through three droplets 
of distilled water (Milli-Q©), blotted again and then stained with 2% uranyl acetate for 10 seconds. Grids were 
blotted and air dried before being imaged in a FEI Tecnai 12 transmission electron microscope at 120 kV using a 
Gatan US1000 CCD camera.
Quantitative PCR. RNA extraction and cDNA preparation were performed as previously 
described49. Samples were run using the Pfaffl method with a standard curve of mixed cDNA50. 
Primer and probe sets were designed by PrimerDesign Ltd. (Southampton, UK) with sequences as fol-
lows: TNF-F GCTCCCTCTCATCAGTTCCA; TNF-R CTCCTCTGCTTGGTGGTTTG; CXCL-1-F 
GCAGACAGTGGCAGGGATT; CXCL-1-R GTGGCTATGACTTCGGTTTGG. Samples were analyzed using a 
Roche Light Cycler 480® (Roche Diagnostics, Welwyn Garden City, UK) and SYBR green technology. Reaction 
efficiency was determined using the standard curve and the analysis was performed using a comparative cycle 
threshold method. Results were relative to the expression of the house keeping gene glyceraldehyde phosphate 
dehydrogenase (GAPDH) and all data were normalized to the corresponding saline group.
IL-1β ELISA. To examine the distribution of IL-1β after injection, animals were injected with human 
recombinant IL-1β as previously described to enable the endogenous production to be distinguished from the 
exogenously administered cytokine. Recombinant human IL-1β is known to bind to rat IL-1R1 with high affin-
ity51. After 2 hours blood was removed by cardiac puncture under terminal anesthesia; the brains were rapidly 
removed, sliced into 3-mm sections and both the injected and non-injected striata were punched out, snap-frozen 
in liquid nitrogen and stored at -80 °C for subsequent extraction and quantification for IL-1β by ELISAs specific 
for human or rat IL-1b (R&D Systems; UK). For optimal extraction of proteins, the tissue was homogenised on 
ice in phosphate buffer containing protease inhibitors [amino-n-caproic acid (100 mM), Na + EDTA (10 mM), 
benzamidine HCl (5 mM), AEBSF (0.2 mM)] at pH 7.4. Homogenates were centrifuged (12,000 g) for 10 min at 
4 °C, and the supernatants were removed and assayed in duplicate immediately, along with calibrated cytokine 
standards. The sensitivities of these ELISA kits were all equal to or better than 15.6 pg/ml. Over 90% of a known 
amount of recombinant IL-1β standard added into normal brain homogenate or plasma (spike) was detected by 
this assay (recovery), indicating that neither known (endogenous antagonists) nor unknown biological factors 
interfere with binding.
Data analysis. One and two-way ANOVA analysis and Student's t-tests were applied as necessary. Analysis 
was performed using GraphPad Prism 5 and SPSS. Data are presented as mean ± SEM.
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